The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at $367m (272 million pounds) spanning five years over the United States' insistence on confidential information.
This rejection came to light after a government memo from December was leaked, revealing that President Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesperson later explained that the United States was seeking genetic material for research and commercial purposes while was not willing to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for continued negotiations to secure a agreement acceptable to all parties so the country's critical HIV programme can be sustained.
Wider Background
This development comes after a comparable situation in neighbouring Kenya, where a court halted a related deal with the US following legal challenges were filed about the security of citizens' health data.
After returning to office recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
The agency had administered aid for the American government, but Trump argued its expenditure was "wasteful" and his administration was pursuing government-to-government deals to boost transparency and responsibility.
As per statements, 16 African countries have to date agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this cooperation might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on antiretroviral therapy through American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding assurance of benefiting from any medical innovations – such as new medicines or tests – that could result from that shared data," Mangwana explained.
"Put simply, our country would supply the basic resources for scientific discovery without any certainty that the final treatments would be available to our people should a future health crisis arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one deals were upending structures previously established through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This system is intended to guarantee that when a country provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the funds to develop them."
Zimbabwe's reservations over the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing discussions with our US partners on how subsequent co-operation might be structured in a manner that honours the independence and interests of each country."
Medical Community Response
Medical experts said it understood the official position, but recommended that talks must proceed considering a large portion of the nation's Aids initiatives relied on international support.
"Where technical issues arise, such as those relating to data governance or agreement terms, these can frequently be resolved through technical clarification and negotiated safeguards," it said.
The situation emphasises the continuing debate between receiving much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.